SOL-MDD-301
Brief description of study
The purpose of this research study is to determine whether the study drug, Solriamfetol, is safe and effective for the treatment of Major Depressive Disorder (MDD). Solriamfetol, also called Sunosi®, is approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
